

Just published

A revised edition of the . . .

BRITISH NATIONAL FORMULARY

1981, Number 2

Compiled by a panel of experts guided by the Joint Formulary Committee under the chairmanship of Professor O. L. Wade, and published jointly by the British Medical Association and The Pharmaceutical Society of Great Britain.

The aim of the B.N.F. is to encourage effective, economic, and rational prescribing. This edition has been thoroughly revised, and includes virtually all of the four thousand or so preparations available for prescribing in the U.K. A new feature is the inclusion of price bands for each preparation, thus enabling the prescriber to compare relative prices of similar preparations. Those preparations which are considered to be less suitable for prescribing are printed in smaller type.

The main part of the book consists of classified notes on drugs and preparations used in the treatment of diseases and conditions. These notes are divided into 15 chapters, each of which is related to a particular system of the human body (cardiovascular, respiratory, etc.) or to another main subject (infections, vaccines, etc.). Each chapter begins with con-

cise notes for prescribers, intended to provide information to doctors, pharmacists, nurses, etc, and to facilitate the selection of suitable treatment. The notes are followed by details of the relevant drugs and preparations.

Other new sections of the B.N.F. aid prescribing in liver diseases and in renal impairment. Appendixes cover drug interactions, intravenous additives, and borderline substances. As in previous editions a Formulary section is included, as is a Dental Practitioners' Formulary. A comprehensive index completes the book.

Because of the introduction of new products and improvement in techniques, and because prices change regularly in an inflationary period, it is intended in the future to publish two editions of the new-style B.N.F. in each year.

Principal contents: Guidance on prescribing. Emergency treatment of poisoning. Classified notes on drugs and preparations: Gastro-intestinal system; Cardiovascular system; Respiratory system; Central nervous system; Infections; Endocrine system; Obstetrics and gynaecology; Malignant disease and immunosuppression; Nutrition and blood; Musculoskeletal and joint diseases; Eye; Ear, nose and oropharynx; Skin; Immunological products and vaccines; Anaesthesia. Drug interactions. Intravenous additives. Borderline substances. Formulary. Dental Practitioners' Formulary. Index of manufacturers. Index.

The new B.N.F. has been prepared for health-care professionals working within the National Health Service. *All doctors working in the N.H.S., and all pharmacies contracted to the N.H.S., will receive copies of the new B.N.F. from the D.H.S.S. free of charge, as will nursing wards, medical schools, and schools of pharmacy.* Additional copies may be purchased from the publishers at £3.80 per copy (which includes postage and packing).

416 pages (paperbound)

September 1981

ISBN: 0 85369 141X £3.80
ISSN: 0260-535X

British Medical Association
The Pharmaceutical Press

B.M.A. House, Tavistock Square, London WC1H 9JP
1 Lambeth High Street, London SE1 7JN

Robert Stevenson House, 1-3 Baxter's Place,
Leith Walk, Edinburgh EH1 3AF, U.K.



The nasal-block buster

FOR COLDS, RHINITIS AND SINUSITIS

ACTIFED TABLETS

triprolidine hydrochloride BP/pseudoephedrine hydrochloride BP

Indications Symptomatic relief of upper respiratory congestion in: the common cold, hay fever, vasomotor and allergic rhinitis, acute sinusitis, otitis barotrauma.

Dosage Three times a day: Adults and children over 12 years: 1 tablet or 10 ml. 6-12 years: 7.5 ml. 1-6 years: 5 ml. 3-12 months: 2.5 ml.

Contra-Indications Actifed* is contraindicated in persons under treatment with MAO inhibitors and within two weeks of stopping such treatment.

Precautions Although at recommended dosage pseudoephedrine has virtually no pressor effects in normotensive subjects, Actifed should be used with caution in patients with cardiovascular disorders. As with other antihistamine-containing

preparations, drowsiness may occur. In some patients the action of antihistamines may be potentiated by alcohol.

Presentation Each Actifed tablet contains 2.5 mg triprolidine hydrochloride and 60 mg pseudoephedrine hydrochloride. PL3/5003.

Each 5 ml of Actifed Syrup contains 1.25 mg triprolidine hydrochloride and 30 mg pseudoephedrine hydrochloride. PL3/5004.

Additional information is available on request.



Wellcome Medical Division
The Wellcome Foundation Ltd., Crewe, Cheshire.

*Trade Mark



Infected
eczema

Pustular
Herpes simplex

Folliculitis

Impetigo

Whenever
antibiotic

CICATRIN* CREAM

Indications Topical broad-spectrum antibacterial. Superficial bacterial

infections of the skin such as impetigo, varicose ulcers, pressure sores, trophic ulcers and burns. **Dosage and administration** A light dusting of the powder or a thin layer of the cream should be applied to the affected area up to three times daily.

Contra-indications, warnings, etc. Contra-indicated in those individuals who have shown hypersensitivity to bacitracin or the neomycin group of antibiotics. Neomycin is potentially ototoxic and nephrotoxic if absorbed from open surfaces.

zinc bacitracin BP neomycin sulphate BP

CICATRIN Cream or Powder contains: Neomycin Sulphate BP 3,300 units, Zinc Bacitracin BP 250 units, L-Cysteine 2 mg, Glycine 10 mg, dl-Threonine 1 mg. CICATRIN Cream (PL 3/5082) is available in tubes of 15 g and 30 g. CICATRIN Powder (PL 3/5081) is available in puffer packs of 15 g and 50 g. Further information is available on request. Calmic Medical Division, The Wellcome Foundation Ltd., Crewe, Cheshire.

Bacitracin is also potentially nephrotoxic. **Presentation** Each gram of

*Trade Mark

The combination of
simple language and straightforward
line drawings has made the

ABC OF OPHTHALMOLOGY


one of the most popular series
of articles in the Medical Practice section
of the British Medical Journal.

All the common problems are covered -
visual defects, squints, glaucoma and
cataracts - together with detailed
instruction on examination, diagnosis
and management.

The articles
have now been
collected into book
form - in exactly
the same format
as they appeared in
the BMJ -
price: Inland £2.50;
Overseas US\$6.25
(Inland £2.00;
Overseas US\$5.00
for BMA members).

AVAILABLE NOW

Order your copy now
From: The Publisher,
British Medical Journal,
BMA House,
Tavistock Square,
London WC1H 9JR
or any leading bookseller




Imodium

TRADEMARK

(loperamide hydrochloride)

symbol of
accuracy
in acute diarrhoea



Imodium's specific action controls diarrhoea, relieving pain and abdominal cramps rapidly and effectively.

A tailored dosage regime means that patients only take Imodium when they really need it, minimising the risk of constipation and encouraging economy of medication. Patients will find Imodium capsules easy to take and the blister pack of just twelve capsules is convenient to carry throughout the working day.

Imodium
Simply Stops Diarrhoea - fast
2 // stat and 1 /
at each loose stool

Further information is available from :



JANSSSEN PHARMACEUTICA
2340 Beerse, Belgium

or

JANSSSEN PHARMACEUTICAL LTD.
Marlow, Bucks. SL7 1ET.

Presentation :

Hard gelatin capsules containing 2 mg loperamide hydrochloride and syrup containing 1 mg loperamide hydrochloride per 5 ml.

Indications :

Imodium* is indicated for the symptomatic control of acute diarrhoea of any aetiology.

Contra-indications and warnings etc. :

There are no specific contra-indications to Imodium*. Studies in animals have shown no abnormal teratogenic effects, however the use of loperamide during pregnancy is subject to the usual precautions. In trials, no side effects have been reported that can reliably be distinguished from the symptoms of the gastro-intestinal disorder being treated. As persistent diarrhoea can be an indicator of potentially more serious conditions, Imodium* should not be used for prolonged periods until the underlying cause of the diarrhoea has been investigated.

Dosage and Administration :

Acute Diarrhoea : Adults : Two capsules initially, followed by one capsule after every loose stool. The usual dosage is 3 to 4 capsules a day, the maximum daily dose should not exceed 8 capsules. **Children :** 4 to 8 years : Syrup 5 ml four times daily until diarrhoea is controlled. In children under 8 years, further investigation may be necessary if diarrhoea has not responded to three days' treatment. 9 to 12 years : Syrup 10 ml (or 1 capsule) four times daily until diarrhoea is controlled.

Basic NHS Cost :

12 capsules (ex 250 pack) 104p. (correct at time of printing)

Product Licence Numbers :

Capsules 0242/0028 - Syrup 0242/0040

fucidin

sodium fusidate B.P.

knows no barriers!

For the treatment of staphylococcal infection



1. Staphylococci form local, often recurrent, lesions, which are protected from destruction by formation of a bio-film and shielded from systemic chemotherapy.

2. Fucidin exerts a potent antibacterial effect even in the presence of large collections of pus, in which it penetrates to penetrate the pus and concentrate.

3. Fucidin, which has the ability to penetrate into the site of infection, is effective against staphylococci in the blood stream.

- Brain abscess
- Hypopyon
- Endophthalmitis
- Lung abscess
- Endocarditis
- Pneumonia with abscess
- Empyema
- Renal carbuncle
- Deep wound infection
- Septic arthritis
- Foreign bodies | grafts
 | prostheses
- Osteomyelitis
- Diabetic gangrene

Indications:
Staphylococcal infections of the skin and soft tissues, including abscesses, furuncles, carbuncles, cellulitis, and infected wounds. Staphylococcal pneumonia, lung abscess, empyema, and osteomyelitis. Staphylococcal endocarditis, abscesses of the brain, and other deep-seated infections. Staphylococcal infections of the eye, including hypopyon and endophthalmitis. Staphylococcal arthritis and septic arthritis. Staphylococcal infections of the urinary tract, including renal carbuncle and pyelitis. Staphylococcal infections of the blood stream.

Contraindications:
Hypersensitivity to sodium fusidate B.P. or to any of the components of the preparation. Patients with severe renal or hepatic impairment. Patients with severe dehydration or electrolyte imbalance. Patients with severe heart failure or other conditions which may be aggravated by the use of sodium fusidate B.P.

Preparations:
Fucidin Tablets, 500 mg. and 1000 mg. (sodium fusidate B.P.). Fucidin Cream, 2% (sodium fusidate B.P.). Fucidin Ointment, 2% (sodium fusidate B.P.). Fucidin Eye Drops, 1% (sodium fusidate B.P.). Fucidin Injection, 500 mg./5 ml. (sodium fusidate B.P.).

References:
1. J. Pharm. Med. (Lond.) 1970, 1, 179A, 1970.
2. J. Pharm. Med. (Lond.) 1970, 1, 179A, 1970.
3. J. Pharm. Med. (Lond.) 1970, 1, 179A, 1970.